美国双特异性抗体市场规模、份额和趋势分析报告：按类型和细分市场预测（2025-2033 年）

美国双特异性抗体市场摘要

2024年美国双特异性抗体市场规模估计为117.8亿美元，预计2033年将达到2,719.5亿美元。

预计从 2025 年到 2033 年，双特异性抗体产业将以 40.1% 的复合年增长率成长。在美国，双特异性抗体产业正经历显着成长，这主要得益于癌症和自体免疫疾病的增加以及对更精准标靶治疗的强劲需求。

根据《自然综述：临床肿瘤学》（2024）报告，目前有超过200种双特异性抗体处于临床前或临床开发阶段。这些抗体大多被设计为免疫细胞衔接器，可针对两种抗原，其双标靶机制展现了其在精准肿瘤治疗中的应用潜力。

此外，美国食品药物管理局(FDA) 对多种双特异性抗体的核准不断增加，也促进了研发投入的增加。例如，2025 年 5 月，辉瑞与 3SBio 公司签署了一项利润丰厚的 SSGJ 707 授权协议，其中包括 12.5 亿美元的首付和高达 48 亿美元的里程碑付款。同样，2025 年 6 月，百时美施贵宝公司与 BioNTech 公司达成合作，共同开发和商业化 BioNTech 公司在研的用于治疗多种固态肿瘤的双特异性抗体 BNT327，该协议价值高达 111 亿美元。该协议包括 15 亿美元的首付款、20 亿美元的保证付款，以及根据研发、监管和商业里程碑支付的最高 76 亿美元的额外款项。

在美国，由于全国癌症病例数量不断增加，双特异性抗体疗法正变得越来越受欢迎。美国血液学会于2024年发表的一项研究调查了564名復发或难治性多发性骨髓瘤患者。其中，202名患者接受了双特异性抗体治疗，包括teclistamab（91%）、talquetamab（14%）和erlanatamab（3%）。这些疗法的应用率从2022年的1例激增至2023年合格患者的45%，并在2024年中期达到54%。这种快速普及与FDA分别于2022年10月和2023年8月核准teclistamab和erlanatamab上市的时间相吻合。

目录

第一章调查方法和范围

第二章执行摘要

第三章美国双特异性抗体市场变数、趋势与范围

• 市场体系展望
  • 母市场展望
  • 相关市场展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
  • 产业挑战
  • 产业机会
• 产业分析工具
  • 波特五力分析
• 打入市场策略

第四章美国双特异性抗体市场：按类型分類的估计和趋势分析

• 美国双特异性抗体市场按类型划分：主要结论
• 2024 年和 2033 年按类型分類的变异分析和市场份额
• 按类型划分，2021-2033 年
  • 发炎性疾病与自体免疫疾病
  • 癌症
  • 其他的

第五章美国双特异性抗体市场竞争格局

• 主要市场参与企业的最新趋势和影响分析
• 公司分类
• 财务业绩
• 产品基准测试
• 公司热力图/定位分析
• 策略规划
• 公司简介
  • Amgen
  • Roche
  • Genentech
  • Janssen
  • Immunocore

U.S. Bispecific Antibodies Market Summary

The U.S. bispecific antibodies market size was estimated at USD 11.78 billion in 2024 and is projected to reach USD 271.95 billion by 2033, growing at a CAGR of 40.1% from 2025 to 2033. The U.S. bispecific antibodies industry is undergoing remarkable growth, driven by the rising burden of cancer and autoimmune diseases and a strong demand for therapies with more precise targeting.

A Nature Reviews Clinical Oncology article (2024) states that over 200 bispecific antibodies are in preclinical or clinical development. Most of these antibodies are designed as immune-cell engagers targeting two antigens, highlighting their potential for precision oncology through dual-target mechanisms.

Furthermore, the rising approval by the U.S. Food and Drug Administration for various bispecific antibodies contributes to the growth of investment in research and development activities. For instance, in May 2025, Pfizer entered a high-value licensing agreement with 3SBio for SSGJ 707, including a USD1.25 billion upfront payment and up to USD 4.8 billion in milestone-based payouts. Similarly, in June 2025, Bristol Myers Squibb partnered with BioNTech in a deal worth up to USD 11.1 billion for the co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 for various solid tumor types, comprising USD 1.5 billion upfront, USD 2 billion in guaranteed payments, and as much as USD 7.6 billion in additional development, regulatory, and commercial milestones.

In the U.S., bispecific antibodies are becoming increasingly popular due to the rising number of cancer cases nationwide. A 2024 study published by the American Society of Hematology reported on 564 patients with relapsed or refractory multiple myeloma. Out of these patients, 202 were treated with bispecific antibodies, including teclistamab (91%), talquetamab (14%), and elranatamab (3%). The adoption of these treatments grew dramatically, from just one patient treated in 2022 to 45% of eligible patients in 2023 and reached 54% by mid-2024. This swift adoption corresponds with the FDA approvals of teclistamab in October 2022 and elranatamab in August 2023.

U.S. Bispecific Antibodies Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. bispecific antibodies market report based on type:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Inflammatory & Autoimmune Disorders
• Cancer
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources & Third-Party Perspectives
  • 1.3.4. Primary Research
• 1.4. Information Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Data Visualization
• 1.6. Data Validation & Publishing

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Bispecific Antibodies Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
  • 3.2.3. Industry Challenges
  • 3.2.4. Industry Opportunities
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
• 3.4. Market Entry Strategies

Chapter 4. U.S. Bispecific Antibodies Market: Type Estimates & Trend Analysis

• 4.1. U.S. Bispecific Antibodies Market Type: Key Takeaways
• 4.2. Type Movement Analysis & Market Share, 2024 & 2033
• 4.3. U.S. Bispecific Antibodies Market Estimates & Forecast, By Type, 2021 To 2033 (USD Million)
  • 4.3.1. Inflammatory & Autoimmune Disorders
    • 4.3.1.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
  • 4.3.2. Cancer
    • 4.3.2.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
  • 4.3.3. Others
    • 4.3.3.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)

Chapter 5. U.S. Bispecific Antibodies Market - Competitive Landscape

• 5.1. Recent Developments & Impact Analysis by Key Market Participants
• 5.2. Company Categorization
• 5.3. Financial Performance
• 5.4. Product Benchmarking
• 5.5. Company Heat Map/ Positioning Analysis
• 5.6. Strategy Mapping
• 5.7. Company Profiles
  • 5.7.1. Amgen
    • 5.7.1.1. Company Overview
    • 5.7.1.2. Financial Performance
    • 5.7.1.3. Product Benchmarking
    • 5.7.1.4. Strategic Initiatives
  • 5.7.2. Roche
    • 5.7.2.1. Company Overview
    • 5.7.2.2. Financial Performance
    • 5.7.2.3. Product Benchmarking
    • 5.7.2.4. Strategic Initiatives
  • 5.7.3. Genentech
    • 5.7.3.1. Company Overview
    • 5.7.3.2. Financial Performance
    • 5.7.3.3. Product Benchmarking
    • 5.7.3.4. Strategic Initiatives
  • 5.7.4. Janssen
    • 5.7.4.1. Company Overview
    • 5.7.4.2. Financial Performance
    • 5.7.4.3. Product Benchmarking
    • 5.7.4.4. Strategic Initiatives
  • 5.7.5. Immunocore
    • 5.7.5.1. Company Overview
    • 5.7.5.2. Financial Performance
    • 5.7.5.3. Product Benchmarking
    • 5.7.5.4. Strategic Initiatives

List of Tables

• Table 1 U.S. Bispecific Antibodies Market Estimates and Forecast, By Type, 2021 - 2033 (USD Million)

List of Figures

• Fig 1 US Bispecific Antibodies Market Segmentation
• Fig 2 Information Procurement
• Fig 3 Primary Research Pattern
• Fig 4 Primary Research Approaches
• Fig 5 Primary Research Process
• Fig 6 Market Snapshot
• Fig 7 Type Segment Snapshot
• Fig 8 Competitive Landscape Snapshot
• Fig 9 US Bispecific Antibodies Market Value, 2024 (USD Million)
• Fig 10 US Bispecific Antibodies Market - Industry Value Chain Analysis
• Fig 11 US Bispecific Antibodies Market Dynamics
• Fig 12 US Bispecific Antibodies Market: Porter's Analysis
• Fig 13 US Bispecific Antibodies Market, By Type: Key Takeaways
• Fig 14 US Bispecific Antibodies Market, By Type: Market Share, 2024 & 2033
• Fig 15 Inflammatory & Autoimmune Disorders Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• Fig 16 Cancer Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• Fig 17 Others Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• Fig 18 Key Company Categorization
• Fig 19 Strategic Framework